Indegene Ltd

Net profit of Indegene declined 6.20% to Rs 102.90 crore in the quarter ended December 2025 as against Rs 109.70 crore during the previous quarter ended December 2024. Sales rose 30.77% to Rs 942.10 crore in the quarter ended December 2025 as against Rs 720.40 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales942.10720.40 31 OPM %16.9318.30 - PBDT174.30166.30 5 PBT134.70146.30 -8 NP102.90109.70 -6 Powered by Capital Market - Live

Indegene today announced that Jill DeSimone, a widely respected global life sciences leader, and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene's Board of Directors. Jill brings over four decades of life sciences leadership, with hands-on experience building and leading large commercial and medical organizations. She has held senior leadership roles at leading biopharma companies, including President of U.S. Oncology at Merck, where she led major businesses and product franchises across global markets. She led the launch of Keytruda, Merck's first true oncology product. Jill has also held leadership roles at Teva and Bristol Myers Squibb. She currently serves on the Boards of several public and private biotech companies and brings a valuable set of experiences to Indegene. Neeraj brings extensive experience in private equity, capital allocation, and portfolio value creation. He is currently a Senior Advisor with Carlyle Asia and previously held leadership roles at Accel Partners' growth investing operations in India and Apax Partners. He has worked closely with boards and management teams to support disciplined growth, inorganic expansion, and sustained value creation across scaled businesses, including healthcare and technology-enabled services.Powered by Capital Market - Live

Indegene will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live

Indegene announced that the company's wholly owned subsidiaries, Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH have, on 31 December 2025, signed a Share Purchase Agreement (SPA) to acquire 100% equity shares in Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)) (Trilogy Canada) (Target Company), wholly owned subsidiary of Trilogy Writing and Consulting GmbH. Consequent to the above Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada) will cease to be the subsidiary of Trilogy Writing and Consulting GmbH and become the wholly owned subsidiary of Indegene, Inc. Trilogy Canada specialises in medical writing. Powered by Capital Market - Live

Net profit of Indegene rose 11.34% to Rs 102.10 crore in the quarter ended September 2025 as against Rs 91.70 crore during the previous quarter ended September 2024. Sales rose 17.09% to Rs 804.20 crore in the quarter ended September 2025 as against Rs 686.80 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales804.20686.80 17 OPM %17.4818.36 - PBDT156.50143.50 9 PBT133.10124.10 7 NP102.1091.70 11 Powered by Capital Market - Live

Indegene will hold a meeting of the Board of Directors of the Company on 30 October 2025.Powered by Capital Market - Live

Indegene announced the expansion of its Consulting Practice, combining its proven strategy and transformation expertise to help life sciences organizations navigate complex, large-scale transformations across the value chain. Life sciences companies operate in a dynamic business environment, amidst rapid technology-driven disruption. They are seeking consulting partners who not only advise on strategy but also work alongside them to implement solutions and deliver measurable outcomes. Indegene's integrated consulting practice addresses this exact need, offering clients both strategic insight and hands-on transformation implementation support. In this context, Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability. This is another key step in the company's journey to meet the evolving needs of the life sciences industry. Indegene has named Gobin Chandra as Head of the Integrated Consulting Practice to lead its next phase of growth. Gobin currently leads Indegene's Europe region and oversees key client relationships. He brings deep transformation advisory experience from Bain & Company and will shape the consulting charter across strategy and transformation services. Indegene has steadily expanded its consulting capabilities over the past decade. The acquisition of DT Consulting in 2020 strengthened the company's strategy consulting expertise across customer experience and digital transformation. In parallel, Indegene has organically built transformation consulting capabilities over the last few years. To scale this further, Indegene has acquired WARN & Co., a UK-based transformation consulting firm, enhancing its ability to drive large-scale business transformations. WARN & Co. brings deep expertise in helping global organizations design and transition to new operating models, systems, and ways of working. Powered by Capital Market - Live

Indegene announced the strategic acquisition of BioPharm, a Pennsylvania-based specialized marketing services agency and part of Omnicom Health Group. This acquisition by ILSL Inc., a subsidiary of Indegene, strengthens Indegene's commercialization portfolio with AdTech, combining AI and digital advertising, enabling pharma companies to drive more precise, scalable, and measurable outcomes. Further, this solidifies Indegene's position as a true category leader in data-driven Omnichannel and Media Space. Founded in 2005, BioPharm's clients include 17 of the world's top 25 biopharma organizations. The agency brings deep expertise in omnichannel strategy, end-to-end media journey - spanning strategy, planning and operations, and data-driven campaign execution -blending analytics, automation, and targeted engagement to deliver turnkey precision marketing solutions.Powered by Capital Market - Live

By embedding Datavant's bespoke data enrichment capabilities into Indegene's NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures, and more efficient recruitment processes for biopharmaceutical organizations. Patient recruitment is one of the biggest challenges in clinical development. This is especially true for rare diseases, where eligible patients are few and scattered. Datavant runs the largest health data retrieval network in the country. It covers more than 80,000 hospitals and clinics and processes over 100 million patient records every year. Indegene offers a range of digital solutions for clinical trial recruitment. Together, the two companies intend to make it easier to identify participants for studies based on specific health data. The result is more eligible participants have an opportunity to connect to the trials designed for their specific health conditions, including patients with rare and complex diseases. The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to randomization ratios, and drive more informed decision-making. Ram Yeleswarapu, SVP, Enterprise Clinical Solutions at Indegene, said: We are doubling down on enhancing our capabilities to deliver digital-first recruitment solutions for clients to transform clinical trial execution. Our partnership with Datavant is a key step in this journey. By integrating secure, real-time access to consented patient medical records into our screening process, we are minimizing one of the greatest challenges in clinical trials ' screen failures at sites due to incomplete and ineffective pre-screening. This collaboration reinforces our positioning as the industry's premier digital-first recruitment partner, empowering sponsors and sites with data-driven approaches that deliver measurable outcomes.' Indegene is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. The company's consolidated net profit increased by 32.73% to Rs 116.40 crore on a 12.46% rise in revenue to Rs 760.80 crore in Q1 FY26 over Q1 FY25. The scrip had risen 0.11% to end at Rs 586.65 on the BSE yesterday. Powered by Capital Market - Live

Datavant, the data collaboration platform trusted for healthcare, announced a strategic partnership with Indegene today to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies. By embedding Datavant's bespoke data enrichment capabilities into Indegene's NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures, and more efficient recruitment processes for biopharmaceutical organizations. Patient recruitment is one of the biggest hurdles in clinical development, particularly in rare diseases where eligible populations are small and dispersed. Datavant operates the nation's largest health data retrieval network, spanning more than 80,000 hospitals and clinics and processing over 100 million patient records annually. Combined with Indegene's suite of digitally powered solutions for clinical trial recruitment, the partnership streamlines the identification of suitable participants for studies based on specific health data criteria. The result is more eligible participants have an opportunity to connect to the trials designed for their specific health conditions, including patients with rare and complex diseases. The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to randomization ratios, and drive more informed decision-making.Powered by Capital Market - Live